Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0357920110450020170
Korean Journal of Pathology
2011 Volume.45 No. 2 p.170 ~ p.174
Distinction of Pulmonary Large Cell Neuroendocrine Carcinoma from Small Cell Lung Carcinoma Using a Panel of Bcl-2, p63, and 34¥âE12
Li Jun-Zhe

Choi Chan
Choi Yoo-Duk
Na Kook-Joo
Abstract
Background : Making the distinction between large cell neuroendocrine carcinoma (LCNEC) and small cell lung carcinoma (SCLC) is difficult in some samples of biopsy tissues, but we have to separate LCNEC from SCLC because the two types of cancer may need different therapy and they have different prognostic implications. Thus far, there are no specific immunohistochemical markers that allow distinguishing these two kinds of tumors.

Methods : We performed an immunohistochemical analysis to study the expressions of p63, Bcl-2, and 34¥âE12 and to investigate whether these 3 molecules have correlations in LCNEC and SCLC. We also evaluated the expression of the neuroendocrine markers chromogranin, synaptophysin and CD56.

Results : A statistical analysis was performed for p63, Bcl-2, and 34¥âE12 in separate and combined panels. According to the combinations of p63, Bcl-2, and 34¥âE12, there were frequent expressions of p63-/Bcl-2+ or Bcl-2+/34¥âE12- in the SCLC, and there was a superior proportion of them in the SCLC rather than that in the LCNEC. The p63-/Bcl-2+ and Bcl-2+/34¥âE12- antibody combinations showed higher specificities compared to any single antibody for diagnosing SCLC.

Conclusions : Bcl-2 and selective p63 or 34¥âE12 made up a most useful panel of markers for making the differential diagnosis of LCNEC and SCLC.
KEYWORD
Large cell neuroendocrine carcinoma, Small cell lung carcinoma, p63, Bcl-2, 34¥âE12
FullTexts / Linksout information
  
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø